April 30, 2013 / 11:21 AM / in 4 years

Zoetis profit beats Street on strong pet product sales

1 Min Read

(Reuters) - Zoetis Inc (ZTS.N), formerly the animal health subsidiary of U.S. pharmaceuticals giant Pfizer Inc (PFE.N), posted a better-than-expected quarterly profit, driven by strong growth in sales of pet products in the United States.

Net income for the first quarter rose 26 percent to $140 million, or 28 cents per share, from $111 million, or 22 cents per share, a year earlier.

Excluding items, it earned 36 cents a share. Analysts expected 33 cents a share, according to Thomson Reuters I/B/E/S.

The results were the first for Zoetis since it went public in February.

The company, which sells drugs for livestock and pets, raised $2.2 billion in the largest IPO by a U.S. company since Facebook Inc (FB.O).

Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below